Bioarctic Ab Stock Fundamentals
| BIOA-B Stock | SEK 189.60 4.20 2.27% |
BioArctic AB fundamentals help investors to digest information that contributes to BioArctic's financial success or failures. It also enables traders to predict the movement of BioArctic Stock. The fundamental analysis module provides a way to measure BioArctic's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BioArctic stock.
BioArctic |
BioArctic AB Company Operating Margin Analysis
BioArctic's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current BioArctic Operating Margin | (0.03) % |
Most of BioArctic's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioArctic AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, BioArctic AB has an Operating Margin of -0.0338%. This is 99.9% lower than that of the Healthcare sector and 99.97% lower than that of the Biotechnology industry. The operating margin for all Sweden stocks is 99.39% lower than that of the firm.
BioArctic AB Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining BioArctic's current stock value. Our valuation model uses many indicators to compare BioArctic value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across BioArctic competition to find correlations between indicators driving BioArctic's intrinsic value. More Info.BioArctic AB is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value BioArctic by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for BioArctic's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.BioArctic Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioArctic's direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BioArctic could also be used in its relative valuation, which is a method of valuing BioArctic by comparing valuation metrics of similar companies.BioArctic is currently under evaluation in operating margin category among its peers.
BioArctic Fundamentals
| Return On Equity | -0.0142 | |||
| Return On Asset | -0.0055 | |||
| Profit Margin | (0.05) % | |||
| Operating Margin | (0.03) % | |||
| Current Valuation | 26.19 B | |||
| Shares Outstanding | 73.73 M | |||
| Shares Owned By Insiders | 48.40 % | |||
| Shares Owned By Institutions | 30.39 % | |||
| Price To Earning | 12.95 X | |||
| Price To Book | 32.29 X | |||
| Price To Sales | 111.27 X | |||
| Revenue | 23.15 M | |||
| Gross Profit | 155.53 M | |||
| EBITDA | (126.63 M) | |||
| Net Income | (119.79 M) | |||
| Cash And Equivalents | 848.4 M | |||
| Cash Per Share | 13.84 X | |||
| Total Debt | 7.79 M | |||
| Debt To Equity | 3.00 % | |||
| Current Ratio | 5.62 X | |||
| Book Value Per Share | 8.92 X | |||
| Cash Flow From Operations | (140.46 M) | |||
| Earnings Per Share | 0.31 X | |||
| Target Price | 393.2 | |||
| Number Of Employees | 61 | |||
| Beta | 0.61 | |||
| Market Capitalization | 26.34 B | |||
| Total Asset | 897.73 M | |||
| Net Asset | 897.73 M |
About BioArctic Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioArctic AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioArctic using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioArctic AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.BioArctic AB , a research intensive biopharmaceutical company, develops disease modifying treatments and diagnostics for neurodegenerative diseases in Sweden. BioArctic AB was founded in 1992 and is headquartered in Stockholm, Sweden. BioArctic is traded on Stockholm Stock Exchange in Sweden.
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in BioArctic Stock
BioArctic financial ratios help investors to determine whether BioArctic Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioArctic with respect to the benefits of owning BioArctic security.